Nemotan 100 tablets 30mg Nimodipine Немотан

Nemotan (nimodipine)

Nemotan contains the active ingredient nimodipine, dihydropyridine calcium channel blocker.

Nemotan Indications

After previous infusion Nemotan®, solution for infusion, for the treatment and prevention of ischemic neurological disturbances caused by vasospasm brain after subarachnoid hemorrhage due to aneurysm rupture.

Contraindications

Use of the drug Nemotan contraindicated in case of individual hypersensitivity to nimodipine or any other drug.

Use of the drug Nemotan, tablets, film-coated membrane, in combination with rifampicin or antiepileptic drugs (phenobarbital, phenytoin, carbamazepine) is contraindicated as concurrent use of drugs leads to a significant reduction of efficacy of Nimotop

Dosage & Administration

After previous infusion therapy with Nemotan, which lasted from 5 to 14 days, prescribed a daily dose of 6 times a day 2 tablets, film coated membrane (6×60 mg nimodipine).

In case of adverse reactions the dose should be reduced, if necessary – to stop the drug.

In the case of a related treatment along with drugs inducing or inhibiting cytochrome system P450 3A4, may require dose adjustment (see. Section “Interaction with other medicinal products and other forms of interaction”).

Patients with hepatic impairment

In case of serious disturbances of liver function, particularly liver cirrhosis, the bioavailability of nimodipine can increase due to lower first-pass effect and reduced metabolic clearance. The action of the drug and the adverse reactions, such as hypotension, these patients may be more pronounced.

In such cases, reduce the dose or, if necessary, consider stopping treatment.

Browse more blood pressure available with international delivery.